Efficacy Study of Methenamine + Methylthioninium Chloride vs Phenazopyridine for the Symptomatic Control of Dysuria
Phase III, Prospective, Multicenter, Single-blind, Randomized, Superiority to Evaluate the Efficacy and Safety of Methenamine Association 250mg + Methylthioninium Chloride 20 mg Compared to Phenazopyridine 100 mg in Symptomatic Control of Dysuria
Sponsor: EMS
Listed as NCT01657448, this PHASE3 trial focuses on Dysuria and remains completed. Sponsored by EMS, it has been updated 7 times since 2016, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Aug 2020 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Sep 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
Status: Not Yet Recruiting → Unknown Status
-
Jan 2017 — Sep 2017 [monthly]
Not Yet Recruiting PHASE3
First recorded
Jun 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EMS
For direct contact, visit the study record on ClinicalTrials.gov .